Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc expected to post a loss of 17 cents a share - Earnings Preview

* Abcellera Biologics Inc  ABCL.OQ   ABCL.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 7 for
the period ending March 31 2024
    * The Vancouver British Columbia-based  company is expected
to
report a 11.1% decrease in revenue to $10.836 million from
$12.19 million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Abcellera Biologics Inc
is for
a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Abcellera
Biologics Inc is $14.50​, above​ its last closing price
of $4.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.13       -0.13      -0.17     Missed  -28.6
 Sep. 30 2023  -0.12       -0.13      -0.10     Beat    25.6
 Jun. 30 2023  -0.11       -0.13      -0.11     Beat    15.4​
 Mar. 31 2023  -0.12       -0.14      -0.14     Met     -3.2
 ​​Dec.        0.00        -0.01      -0.10     Missed  -1,804
 31 2022                                                .8
 Sep. 30 2022  0.05        0.05       0.08      Beat    76.1​
 Jun. 30 2022  -0.01       -0.02      -0.02     Met     -28.5
 Mar. 31 2022  0.40        0.38       0.54      Beat    40.6
 This summary was machine generated May 4 at 02:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on AbCellera Biologics

See all news